community download

Presentation: Meeting the manufacturing challenges for dengue vaccine demand in endemic and non-endemic

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Meeting the manufacturing challenges for dengue vaccine demand in endemic and non-endemic
Joe Santangelo, COO, Inviragen Inc. Joined us at the World Vaccine Congress 2012 in Washington to give details on Inviragen’s current vaccine pipeline. The current focus for the company is the development of vaccines for infectious diseases with a focus on emerging economies. With international operations with offices in Colorado, Wisconsin and Singapore, the vaccine pipeline currently has four key vaccines in development: vaccine for Dengue, EV71, Japanese Encephalitis and Chikungunya. Alongside these vaccines, research programs are currently operational for HPV, Avian and swine influenza, West Nile and Plague/ smallpox for biodefense.
 
This presentation focuses on the Dengue Vaccine. The ideal vaccine could be administered in one or two easy doses; it would be safe and encourage immunogenicity. In terms of distribution and use, thermal stability is required especially as the vaccine would be distributed across a wide area. A needle-free delivery option could also be beneficial.
 
DENVax is a DEN-2 PDK-53 ideal dengue vaccine backbone that may play a role in cellular immunity.  Chimeras retain attenuating phenotypes and are immunogenic, whilst the tetravalent vaccine formulations are safe and generate neutralizing antibodies in preclinical models. It performed well in the phase 1 trials with encouraging preliminary safety and immunogenicity data.  
 
Why not download the full presentation and discover more about